Richard Law
Stock Analyst at Goldman Sachs
(0.75)
# 3,952
Out of 5,127 analysts
73
Total ratings
14.29%
Success rate
-5.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLTX MoonLake Immunotherapeutics | Downgrades: Sell | $8 → $10 | $15.62 | -35.98% | 5 | Jan 15, 2026 | |
| RCUS Arcus Biosciences | Upgrades: Buy | $16 → $28 | $20.78 | +34.74% | 1 | Jan 13, 2026 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $67 | $47.61 | +40.73% | 2 | Jan 12, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $26 → $38 | $23.37 | +62.60% | 7 | Dec 11, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $120 → $135 | $102.15 | +32.16% | 1 | Nov 18, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Neutral | $19 → $29 | $26.88 | +7.89% | 2 | Oct 30, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $32 → $52 | $31.07 | +67.36% | 7 | Sep 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $27 → $30 | $30.06 | -0.20% | 4 | Aug 7, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $4.48 | -33.04% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.24 | +301.23% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $31 | $24.63 | +25.86% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $30 | $28.75 | +4.35% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $19.57 | -43.78% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $26.95 | +74.40% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $48.83 | +29.02% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $79.49 | -53.45% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $11.91 | +538.12% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $1.78 | +686.52% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $13.44 | +353.87% | 4 | May 8, 2023 |
MoonLake Immunotherapeutics
Jan 15, 2026
Downgrades: Sell
Price Target: $8 → $10
Current: $15.62
Upside: -35.98%
Arcus Biosciences
Jan 13, 2026
Upgrades: Buy
Price Target: $16 → $28
Current: $20.78
Upside: +34.74%
Crinetics Pharmaceuticals
Jan 12, 2026
Upgrades: Buy
Price Target: $67
Current: $47.61
Upside: +40.73%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $26 → $38
Current: $23.37
Upside: +62.60%
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $102.15
Upside: +32.16%
Arcutis Biotherapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $19 → $29
Current: $26.88
Upside: +7.89%
Mineralys Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $31.07
Upside: +67.36%
Viridian Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $30.06
Upside: -0.20%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $4.48
Upside: -33.04%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.24
Upside: +301.23%
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $24.63
Upside: +25.86%
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $28.75
Upside: +4.35%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $19.57
Upside: -43.78%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $26.95
Upside: +74.40%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $48.83
Upside: +29.02%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $79.49
Upside: -53.45%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $11.91
Upside: +538.12%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $1.78
Upside: +686.52%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $13.44
Upside: +353.87%